What is the pancreatitis risk with GLP-1s?

Acute pancreatitis — inflammation of the pancreas — appears on every GLP-1 label as a warning, so here’s the proportionate picture. The numbers: in the big obesity trials, acute pancreatitis occurred in roughly 0.2–0.3% of participants, with rates similar between drug and placebo arms in several analyses. Meta-analyses of the class have generally not confirmed a significant excess risk versus comparators. Confounding is real: obesity, gallstones, and rapid weight loss all independently raise pancreatitis risk — and gallstones, which GLP-1 therapy can promote via rapid loss, are themselves a leading pancreatitis cause. The precautionary rules that exist anyway: 1. Prior pancreatitis → generally no GLP-1. Most protocols treat any pancreatitis history as exclusionary; some clinicians make case-by-case exceptions for distant, resolved, clearly gallstone-caused episodes — that’s a specialist call, not a checkbox. 2. Know the symptom signature: severe, persistent upper-abdominal pain — often boring through to the back, often with vomiting, sometimes worse after eating. Distinct from routine GLP-1 nausea by severity and persistence: titration nausea waxes and wanes; pancreatitis pain arrives and stays. 3. Response if suspected: stop the medication and get same-day medical care (diagnosis is a simple blood test, lipase, plus imaging). Confirmed GLP-1-era pancreatitis usually ends that therapy permanently. Risk-stacking to discuss with your prescriber: heavy alcohol use (an independent pancreatitis driver — alcohol on GLP-1s), very high triglycerides, and active gallstone disease. None is an automatic no; all belong in the screening conversation a legitimate program conducts.